Issue 12/2018
Content (11 Articles)
Acknowledgement to Referees
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Jacoline C. Bouvy, Pall Jonsson, Diana O’Rourke, Antonella Santuccione Chadha, Niklas Hedberg, Amr Makady, Entela Xoxi, Christine Gispen-de Wied, Anja Schiel, Raj Long, John Gallacher
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Juliane Gust, Agne Taraseviciute, Cameron J. Turtle
Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis
Pierre Ellul, Richard Delorme, Samuele Cortese
A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms
Maira Aguiar Werneck, Guilherme Trevizan Kortas, Arthur Guerra de Andrade, João Mauricio Castaldelli-Maia
Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
Marita Zimmermann, Elizabeth Brouwer, Jeffrey A. Tice, Matt Seidner, Anne M. Loos, Shanshan Liu, Richard H. Chapman, Varun Kumar, Josh J. Carlson
Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential
Alexander Klistorner, Yi Chai, Letizia Leocani, Philipp Albrecht, Orhan Aktas, Helmut Butzkueven, Tjalf Ziemssen, Focke Ziemssen, Jette Frederiksen, Lei Xu, Diego Cadavid, Helmut Butzkueven, Ray Garrick, Ludo Vanopdenbosch, Jette Frederiksen, Orhan Aktas, Philipp Albrecht, Focke Ziemssen, Tjalf Ziemssen, Giancarlo Comi, Bernardo Sánchez Dalmau, Magnus Andersson, Gordon T. Plant, Tim Matthews, Graeme Williams
Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis
Mark Gudesblatt, Karl Wissemann, Myassar Zarif, Barbara Bumstead, Lori Fafard, Jeffrey Wilken, Karen Blitz, Marijean Buhse, Sourav Santra, Christophe Hotermans, Lily Lee
Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis
Mark Gudesblatt, Karl Wissemann, Myassar Zarif, Barbara Bumstead, Lori Fafard, Jeffrey Wilken, Karen Blitz, Marijean Buhse, Sourav Santra, Christophe Hotermans, Lily Lee
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
John A. Hey, Petr Kocis, Jakub Hort, Susan Abushakra, Aidan Power, Martin Vyhnálek, Jeremy Y. Yu, Martin Tolar